Verilumia 
Moderna, Merck report melanoma vaccine trial results
Moderna and Merck said a personalized mRNA vaccine, added to Keytruda after surgery for high-risk melanoma, reduced the relative risk of recurrence or death by 42% over the first two years in a Phase 3 trial...
